General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal
Autor: | Elizabeth M Curtis, Claire Holmes, Stephen J Woolford, Cyrus Cooper, Nicholas C. Harvey |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Health Knowledge Attitudes Practice Epidemiology Endocrinology Diabetes and Metabolism Cost-Benefit Analysis Osteoporosis 030209 endocrinology & metabolism Risk Assessment Reimbursement Mechanisms 03 medical and health sciences 0302 clinical medicine Absorptiometry Photon Secondary Prevention Medicine Humans In patient Adverse effect Intensive care medicine Reimbursement Quality of Health Care Quality of Care in Osteoporosis (S Silverman and J Curtis Section Editors) Fragility fracture Bone Density Conservation Agents Treatment gap business.industry Adverse effects Health Policy Multimorbidity Guideline medicine.disease 3. Good health Primary Prevention Fracture Policy Practice Guidelines as Topic Bisphosphonate-Associated Osteonecrosis of the Jaw 030101 anatomy & morphology Clinical Competence Guideline Adherence business Femoral Fractures Osteoporotic Fractures Screening measures |
Zdroj: | Current Osteoporosis Reports |
ISSN: | 1544-2241 |
Popis: | Purpose of Review The assessment of fracture risk and use of antiosteoporosis medications have increased greatly over the last 20–30 years. However, despite this, osteoporosis care remains suboptimal worldwide. Even in patients who have sustained a fragility fracture, fewer than 20% actually receive appropriate antiosteoporosis therapy in the year following the fracture. There is also evidence that treatment rates have declined substantially in the last 5–10 years, in many countries. The goal of this article is to consider the causes for this decline and consider how this situation could be remedied. Recent Findings A number of possible reasons, including the lack of prioritisation of osteoporosis therapy in ageing populations with multimorbidity, disproportionate concerns regarding the rare side effects of anti-resorptives and adverse changes in reimbursement in the USA, have been identified as contributing factors in poor osteoporosis care. Summary Improved secondary prevention strategies; screening measures (primary prevention) and appropriate, cost-effective guideline and treatment threshold development could support the optimisation of osteoporosis care and prevention of future fractures. |
Databáze: | OpenAIRE |
Externí odkaz: |